An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06991556 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Hormone-sensitive Prostate Cancer

Interventions

DRUG: JSB462
DRUG: Abiraterone
DRUG: Enzalutamide

Sponsor

Novartis Pharmaceuticals